104 related articles for article (PubMed ID: 11333516)
1. [Incidence of extrapyramidal symptoms during treatment with olanzapine, haloperidol and risperidone: results of an observational study].
Sacristán JA; Gómez JC; Ferre F; Gascón J; Pérez Bravo A; Olivares JM
Actas Esp Psiquiatr; 2001; 29(1):25-32. PubMed ID: 11333516
[TBL] [Abstract][Full Text] [Related]
2. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.
Sacristán JA; Gómez JC; Montejo AL; Vieta E; Gregor KJ
Clin Ther; 2000 May; 22(5):583-99. PubMed ID: 10868556
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.
Kennedy JS; Jeste D; Kaiser CJ; Golshan S; Maguire GA; Tollefson G; Sanger T; Bymaster FP; Kinon BJ; Dossenbach M; Gilmore JA; Breier A
Int J Geriatr Psychiatry; 2003 Nov; 18(11):1013-20. PubMed ID: 14618553
[TBL] [Abstract][Full Text] [Related]
4. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
Hatta K; Otachi T; Fujita K; Morikawa F; Ito S; Tomiyama H; Abe T; Sudo Y; Takebayashi H; Yamashita T; Katayama S; Nakase R; Shirai Y; Usui C; Nakamura H; Ito H; Hirata T; Sawa Y;
Schizophr Res; 2014 Sep; 158(1-3):213-22. PubMed ID: 25086659
[TBL] [Abstract][Full Text] [Related]
6. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.
Carlson CD; Cavazzoni PA; Berg PH; Wei H; Beasley CM; Kane JM
J Clin Psychiatry; 2003 Aug; 64(8):898-906. PubMed ID: 12927004
[TBL] [Abstract][Full Text] [Related]
7. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
Tran PV; Dellva MA; Tollefson GD; Beasley CM; Potvin JH; Kiesler GM
J Clin Psychiatry; 1997 May; 58(5):205-11. PubMed ID: 9184614
[TBL] [Abstract][Full Text] [Related]
8. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.
Beasley CM; Tollefson G; Tran P; Satterlee W; Sanger T; Hamilton S
Neuropsychopharmacology; 1996 Feb; 14(2):111-23. PubMed ID: 8822534
[TBL] [Abstract][Full Text] [Related]
9. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.
Crawford AM; Beasley CM; Tollefson GD
Schizophr Res; 1997 Jul; 26(1):41-54. PubMed ID: 9376336
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
11. Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine.
Schillevoort I; de Boer A; Herings RM; Roos RA; Jansen PA; Leufkens HG
Ann Pharmacother; 2001 Dec; 35(12):1517-22. PubMed ID: 11793611
[TBL] [Abstract][Full Text] [Related]
12. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study).
García-Cabeza I; Gómez JC; Sacristán JA; Edgell E; González de Chavez M
BMC Psychiatry; 2001; 1():7. PubMed ID: 11835695
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.
Einarson TR; Vicente C; Zilbershtein R; Piwko C; Bø CN; Pudas H; Jensen R; Hemels ME
Nord J Psychiatry; 2014 Aug; 68(6):416-27. PubMed ID: 24274837
[TBL] [Abstract][Full Text] [Related]
14. Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients.
Bobes J; Gibert J; Ciudad A; Alvarez E; Cañas F; Carrasco JL; Gascón J; Gómez JC; Gutiérrez M
Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):473-81. PubMed ID: 12691783
[TBL] [Abstract][Full Text] [Related]
15. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
Einarson TR; Maia-Lopes S; Goswami P; Bereza BG; Van Impe K
J Med Econ; 2016 Sep; 19(9):913-21. PubMed ID: 27124697
[TBL] [Abstract][Full Text] [Related]
16. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia.
Gómez JC; Sacristán JA; Hernández J; Breier A; Ruiz Carrasco P; Antón Saiz C; Fontova Carbonell E
J Clin Psychiatry; 2000 May; 61(5):335-43. PubMed ID: 10847307
[TBL] [Abstract][Full Text] [Related]
17. Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol.
Inada T; Beasley CM; Tanaka Y; Walker DJ
Int Clin Psychopharmacol; 2003 Jan; 18(1):39-48. PubMed ID: 12490774
[TBL] [Abstract][Full Text] [Related]
18. Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol.
Purdon SE; Woodward N; Lindborg SR; Stip E
Psychopharmacology (Berl); 2003 Sep; 169(3-4):390-7. PubMed ID: 12827347
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.
Tollefson GD; Sanger TM; Beasley CM; Tran PV
Biol Psychiatry; 1998 Jun; 43(11):803-10. PubMed ID: 9611669
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
Sikich L; Hamer RM; Bashford RA; Sheitman BB; Lieberman JA
Neuropsychopharmacology; 2004 Jan; 29(1):133-45. PubMed ID: 14583740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
